Paclitaxel-Carboplatin Alone or With M2ES for Non-Small-Cell Lung Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01527864
Recruitment Status : Unknown
Verified February 2012 by Protgen Ltd. Recruitment status was: Recruiting
A phase II, multicenter, randomized, double-blind, placebo-controlled study was carried out. Patients were randomly assigned to the treatment (PC + pegylated endostatin) or the control group (PC+ placebo). The efficacy was evaluated every six weeks.Follow-up continued until disease progression or death.
Condition or disease
Non Small Cell Lung Cancer
Drug: pegylated endostatin and Paclitaxel-CarboplatinDrug: Placebo and Paclitaxel-Carboplatin
A randomized phase 2 study, involving patients with advanced non-small-cell lung cancer who had not previously received chemotherapy, compared paclitaxel and carboplatin Plus placebo with paclitaxel and carboplatin plus PEGylated endostatin, with PEGylated endostatin at a dose of 10 mg/m2 intravenously every weeks.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Histologically or cytologically confirmed, newly diagnosed stage IIIB or stage IV cancer or recurrent non-small-cell lung cancer for which they had not received chemotherapy, targeted therapy.
Prior radiation therapy was allowed provided that the only sites disease were not located in lung.
Measurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST).
≥18 years of age.
ECOG performance status of 0 or 1.
Life expectancy of at least 12 weeks.
Adequate hematologic, hepatic, and renal function.
Patients are voluntary to participate and sigh the informed contents.
Major surgery within the prior 4 weeks.
Participating any clinical trial within the prior 4 weeks.
Patients had clinically apparent CNS disease ( primary brain tumors, tumor related apoplexy, CNS metastases, carcinomatous meningitis.)
Another active malignancy, or any history of other malignancy within the past 3 years except for nonmelanoma skin cancer and carcinoma in situ of the cervix.
Pregnant or lactating women.
Radiation therapy have not been completed 4 weeks before enrollment.
Pulmonary embolus, deep venous thrombosis or bleeding diathesis.
Uncontrolled intercurrent illness as following: prior or ongoing uncontrolled hypertension;angina pectoris; congestive cardiac failure; myocardial ischemia, infarction, uncompensated coronary artery disease within the past 12 months; Uncontrolled arrhythmia; Uncontrolled diabetes mellitus; Uncontrolled infection.
Grade 2 hemoptysis within the past 6 months.
Acute or chronic renal disease.
Active hepatitis or HIV.
ECG: QTC ≥ 480 ms.
Patients on therapeutic doses of heparin.
Other conditions that are regarded for exclusion by the investigator.